Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up

A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.

By Kelly Bilodeau • March 23, 2022

Why Astellas is adopting a 'focus area approach' to partnerships

Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

By Kim Ribbink • March 22, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Psychedelics without the party: Inside MindMed's LSD makeover

MindMed’s CEO, Robert Barrow, on the company’s latest moves to ‘change the world’ with psychedelics.

By Alexandra Pecci • March 21, 2022

Attralus' medical officer believes systemic amyloidosis could be 'solvable'

Gregory Bell is not just aiming to treat amyloidosis, but eventually cure it.

By Robin Robinson • March 18, 2022

COVID-19 trials aren't the only studies that can achieve super speed

Is it possible to enroll clinical trials 10 times faster than the industry’s average speed? Elligo Health Research thinks so.

By Kelly Bilodeau • March 15, 2022

Medigene's CEO on striking a collaboration deal with BioNTech

The two companies recently announced a $29 million collaboration. 

By Jared Whitlock • March 15, 2022

Clearing hurdles in rare cancer drug development

Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

By Kim Ribbink • March 14, 2022

Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

By Taren Grom • March 14, 2022

Ultragenyx's CEO on building a 'next-gen' rare disease company

How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

By Kim Ribbink • March 9, 2022

Woman of the Week: Genentech's Quita Highsmith

Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.

By Taren Grom • March 9, 2022

Horizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride

Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.

By Alexandra Pecci • March 8, 2022

Two key factors behind NYC's record-setting rise in healthcare funding

According to a new report, women’s and digital health led to an explosion in funding last year in NYC.

By Robin Robinson • March 7, 2022

Are patients happy? This simple question could shake up clinical trials

The migration to DCTs is helping uncover critical gaps in patient experience.

By Kelly Bilodeau • March 4, 2022

Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started

The company’s CEO on the road ahead for AI capabilities in pharma.

By Meagan Parrish • March 4, 2022

Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter

With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.

By Taren Grom • March 2, 2022

The 2022 PharmaVoice 100 — new look, same drive for excellence

Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.  

By Taren Grom • Feb. 28, 2022

Candel's CEO looks to help ignite a new era of cancer treatments

Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.

By Taren Grom • Feb. 28, 2022

Why plasma derived therapies have a unique edge in rare diseases

Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.

By Kim Ribbink • Feb. 25, 2022

Guadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues

A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company. 

By Robin Robinson • Feb. 25, 2022

Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market

The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.

By Kelly Bilodeau • Feb. 23, 2022

QSAM's rare cancer treatment could be a game-changer

For patients with osteosarcoma, amputation can be the only option — but QSAM's CEO hopes to change that.

By Alexandra Pecci • Feb. 17, 2022

Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler

Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.

By Taren Grom • Feb. 16, 2022

How Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'

Why sexual health and telemedicine are key to the company's goals in oncology.

By Meagan Parrish • Feb. 16, 2022

How a 'powerful form' of data capture is transforming pharma labs

AnIML, an open data format, is helping the industry build labs of the future.

By Robin Robinson • Feb. 15, 2022

Industry executives on the milestone moments shaping pharma's future

Scientific, technological, and communication changes that are making a permanent impact on the industry.

By Taren Grom • Feb. 9, 2022